ANTI-RNA VIRAL PHARMACEUTICAL COMPOSITION AVIFAVIR EFFECTIVE, INTER ALIA, AGAINST SARS-COV-2
This invention relates to a novel anti-RNA virus, including anti-SARS-CoV-2 virus, pharmaceutical composition Avifavir in tablets or capsules containing less than 50 wt % of micronized favipiravir, with the remainder being excipients.Medicinal product Avifavir for the prevention and treatment of COVID-19 coronaviral disease, said medicinal product being a pharmaceutical composition in coated tablets containing 200 mg, 300 mg, 400 mg, or 600 mg of micronized favipiravir (less than 40-45%) with a particle size of less than 60 µm, with the remainder being excipients..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Europäisches Patentamt - (2021) vom: 29. Dez. Zur Gesamtaufnahme - year:2021 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
IVASHCHENKO ANDREY ALEXANDROVICH [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2021-12-29, Last update posted on www.tib.eu: 2023-06-29, Last updated: 2023-07-08 |
|---|
| Patentnummer: |
EP3928778 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA013529161 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA013529161 | ||
| 003 | DE-627 | ||
| 005 | 20230708161251.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230215s2021 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA013529161 | ||
| 035 | |a (EPA)EP3928778 | ||
| 035 | |a (EPA)72421927 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a IVASHCHENKO ANDREY ALEXANDROVICH |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a ANTI-RNA VIRAL PHARMACEUTICAL COMPOSITION AVIFAVIR EFFECTIVE, INTER ALIA, AGAINST SARS-COV-2 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2021-12-29, Last update posted on www.tib.eu: 2023-06-29, Last updated: 2023-07-08 | ||
| 520 | |a This invention relates to a novel anti-RNA virus, including anti-SARS-CoV-2 virus, pharmaceutical composition Avifavir in tablets or capsules containing less than 50 wt % of micronized favipiravir, with the remainder being excipients.Medicinal product Avifavir for the prevention and treatment of COVID-19 coronaviral disease, said medicinal product being a pharmaceutical composition in coated tablets containing 200 mg, 300 mg, 400 mg, or 600 mg of micronized favipiravir (less than 40-45%) with a particle size of less than 60 µm, with the remainder being excipients. | ||
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a SAVCHUK NIKOLAY FILIPPOVICH |4 aut | |
| 700 | 0 | |a IVACHTCHENKO ALENA ALEXANDROVNA |4 aut | |
| 700 | 0 | |a IVACHTCHENKO ALEXANDRE VASILIEVICH |4 aut | |
| 700 | 0 | |a IL'IN ALEKSEI PETROVICH |4 aut | |
| 700 | 0 | |a KRAVCHENKO DMITRII VLADIMIROVICH |4 aut | |
| 700 | 0 | |a PAPAZOVA NATALIA ALEKSANDROVNA |4 aut | |
| 700 | 0 | |a SITDEKOV TAGIR ALIEVICH |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2021) vom: 29. Dez. |
| 773 | 1 | 8 | |g year:2021 |g day:29 |g month:12 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/72421927/publication/EP3928778A1?q=EP3928778 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2021 |b 29 |c 12 |
| 951 | |a AR | ||
| 952 | |j 2021 |b 29 |c 12 | ||